Completion rates of treatment for latent tuberculosis infection in Quebec, Canada From 2006 to 2010

Canadian Journal of Public Health

Volumn 104, Issue 3, 2013, Pages

  Rivest, Paul ^a,b   Street, Maria Constanza ^a   Allard, Robert ^a,c  

^a Agence de la sante et des services sociaux de Montreal   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Adherence; Compliance; Isoniazid; Treatment; Tuberculosis

Indexed keywords

EID: 84879560272     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.17269/cjph.104.3643     Document Type: Article

References (16)

1. Public Health Agency of Canada. Tuberculosis in Canada 2010 - Pre-release. Ottawa, ON: Ministry of Public Works and Government Services, 2011. Available at: http://www.publichealth.gc.ca/tuberculosis (Accessed April 2, 2012).
2. Public Health Agency of Canada. Guidance for Tuberculosis Prevention and Control Programs in Canada. Ottawa: Ministry of Public Works and Government Services, 2011.
3. Public Health Agency of Canada. Canadian Tuberculosis Standards. Ottawa: Ministry of Public Works and Government Services, 2007. Available at: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/pdf/tbstand07e.pdf (Accessed April 2, 2012).
4. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: Systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008;12(11):1235-54.
5. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: Outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003;7(Suppl 3):S384-S390.
6. Reichler MR, Reves R, Bur S, Ford J, Thompson V, Mangura B, et al. Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States. South Med J 2002;95:414-20.
7. Anger HA, Proops D, Harris TG, Li J, Kreiswirth BN, Shashkina E, Ahuja SD. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Clin Infect Dis 2012;54:1287-95.
8. Cain KP, Garman KN, Laserson KF, Ferrousier-Davis OP, Miranda AG, Wells CD, Haley CA. Moving toward tuberculosis elimination: Implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med 2012;186(3):273-79.
9. Goldberg SV, Wallace J, Jackson JC, Chaulk CP, Nolan CM. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004;8:76-82.
10. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of Rifampin for 4 months versus Isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445-49.
11. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of Rifampin. Chest 2006;130:1712-17.
12. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with Rifampin vs Isoniazid for treatment of latent tuberculosis: A retrospective study. Arch Intern Med 2006;166:1863-70.
13. Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137(2):401-9.
14. Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ 2011;183(3):E173-E179.
15. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of Rifapentine and Isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66.
16. Centers for Disease Control and Prevention. Recommendations for use of an Isoniazid-Rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR 2011;60(48):1650-53.